CellCeutix pharmaceutical company

WILMINGTON, Mass.--(BUSINESS WIRE)--Cellceutix (OTCBB: CTIX) President and CSO Dr. Krishna Menon, lead developer of Eli Lilly (NYSE: LLY) cancer compounds Gemzar� and Alimta�, recently conducted a pooled analysis of animal tests of Cellceutix's lead candidate, Kevetrin�, against Head and Neck cancer SCC-15, a squamous cell carcinoma. The results demonstrated that compared with controls, Kevetrin as solo treatment produced tumor reduction of 31.5% and when administered sequentially with radiation, it produced tumor reduction of 73.7%. The results offer hope against the sixth most common cancer globally but one that headlines few pipelines.

Dr. Menon's recent analysis pooled the results of three experiments that were conducted with the same protocol at three different locations, KARD Scientific in Wilmington, MA, Toxicone, in Hyderabad, India and the University of British Columbia. In each of the experiments, radiation was administered alone, and Kevetrin was administered alone and sequentially with radiation in nude mice with human squamous cell carcinoma SCC-15. Both Kevetrin and Kevetrin combined with radiation showed statistically significant tumor reduction compared to the controls (p<.003 using the Student T-test). The results of the experiments at Toxicone and the University of British Columbia confirmed the findings of Dr. Menon's original experiment at KARD. In the pooled analysis, both Kevetrin and Kevetrin administered sequentially with radiation also showed statistically significant tumor reduction compared with the controls (p<.003 using the Student T-test.) [Radiation alone also showed a statistically significant tumor reduction of 36.8% compared to controls.]

About Cellceutix
A preclinical cancer and anti-inflammatory drug developer, Cellceutix owns the rights to six potential pharmaceutical products, including four invented by its President and CSO Dr. Krishna Menon, RCM, PhD, VMD, a 1999 Eli Lilly (NYSE: LLY) Employee of the Year. Cellceutix is chaired and CEO'd by George Evans, JD, MBA, a former Pfizer (NYSE: PFE) Associate General Counsel and Senior VP, General Counsel Human Health (Pfizer's prescription drug division).

This press release may contain forward-looking statements. Cellceutix wants to remind readers that actual results may differ and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For more information, please visit the company's home on the web, www.cellceutix.com, and review its filings with the Securities and Exchange Commission.

Kevetrin has not been studied in humans. Readers should be aware that positive results in animal tests do not necessarily mean that a drug will work in humans.

-----------------------------------------

Pooled Analysis of Kevetrin Efficacy in Nude Mice with SCC-15 Head and Neck Cancer

Methods

Three experiments were conducted using the same protocol at Kard Scientific, Wilmington, MA, Toxicone in Hyderabad, India and at the University of British Columbia.  In each experiment there were four arms, control, Kevetrin alone, radiation alone, and Kevetrin administered sequentially with radiation.  Each arm included ten nude mice with Head and Neck cancer SCC-15, a squamous cell carcinoma.  Tumor reduction was measured every other day and calculated, until it reached 1500 mgms, starting from approximately 100 mgms.  The results of the experiments were pooled and means and standard deviations were calculated.  Statistical evaluations of active arms compared to control were performed using the Student T-test.

Results

In the pooled analysis, the tumor Reduction in percentage compared to control was:

1. Radiation alone -36.8% (p<0.003)

2. Kevetrin alone � 31.5%  (p<0.003)

3. Kevetrin + Radiation � 73.7% (p<0.003).

The improvements in the active arms compared to controls were also statistically significant in the individual experiments.


Analysis


In this analysis, Kevetrin alone, radiation alone and Kevetrin administered sequentially with radiation were effective in reducing tumor size.  There appeared to be a synergistic effect with Kevetrin administered sequentially with radiation.  Based on this analysis, Kevetrin appears to be a viable candidate for development for the treatment of head and neck cancer.